New Delhi, May 13 -- Isomorphic Labs, the AI-first drug discovery company founded by Demis Hassabis, has raised $2.1 billion in a Series B funding round as competition intensifies around artificial intelligence-driven healthcare and pharmaceutical research.

The funding round was led by Thrive Capital and included participation from existing investors Alphabet and GV (formerly Google Ventures), alongside new backers including MGX, Temasek, CapitalG and the UK Sovereign AI Fund.

Demis Hassabis was the co-founder and CEO of DeepMind before the AI research company was acquired by Google in 2014 and later integrated into the broader Google DeepMind structure. He currently serves as CEO of Google DeepMind while also leading Isomorphic Labs as...